Astellas Pharma

Astellas Pharma Europe | March 01, 2016

Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. (TSE:4503), is pleased to announce that Mr Yukio Matsui has been appointed as President of EMEA Operations, with responsibility for the company's commercial operations inEurope, the Middle East and Africa. Yukio will assume his new position on 1st April 2016. Since April 2015, Yukio has served as Senior Vice President, Head of Marketing Strategy for Astellas’ global strategic products....

Astellas Pharma Europe | April 01, 2016

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and LEO Pharma A/S (President and CEO: Gitte P. Aabo, “LEO Pharma”) today announced that the two companies completed the relevant closing conditions on March 31, 2016 to allow the transfer of the Astellas’ global dermatology business to LEO Pharma from 0 a.m. on April 1....

Astellas Pharma Europe | October 14, 2016

The World Anti-Doping Agency (President: Sir Craig Reedie, “WADA”) and Astellas Pharma Inc. (TSE: 4503: President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced a global agreement to partner on the prevention of misuse and abuse of medicines f or doping in sports. Doping in sports relies primarily on the misuse and abuse of commercially available medicines, as well as compounds in development that are not as well-known or easily detected....

Astellas Pharma Europe | October 28, 2016

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for Astellas to acquire Ganymed. The transaction would enable Astellasto continue to build upon its leading oncology franchise as a platform for sus...